Concert Pharmaceuticals Profit Margin

Concert Pharmaceuticals posts a profit margin of -117455.64% as of September 2022. That compares with -203.59% in the prior-year period — down 57593.4% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Concert Pharmaceuticals's profit margin was -203.59%. The latest reading is -117455.64% — a 57593.4% year-over-year decrease (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Concert Pharmaceuticals's -117455.64% is lower that level. That is roughly 845525.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Concert Pharmaceuticals's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -117455.64% as of September 2022; use YoY and peer views to separate noise from signal.

Context for CNCE's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Concert Pharmaceuticals's other metric pages and overview cover the third.